Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesDasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily
Cancer, 06/23/09
Kantarjian H et al. - In a trial to assess the use of dasatinib and high-dose imatinib in chronic-phase chronic myeloid leukemia (CP-CML) resistant to imatinib, it was reported that after 2 yrs of follow-up, dasatinib demonstrated durable responses and improved response and progression-free survival (PFS) rates relative to high-dose imatinib.
Methods- A phase 2, open-label study was initiated of 150 pts with imatinib-resistant CP-CML who were randomized (2:1) to receive either dasatinib 70 mg twice daily (n=101) or high-dose imatinib 800 mg (400 mg twice daily; n=49).
- At a minimum follow-up of 2 yrs, dasatinib demonstrated higher rates of complete hematologic response (93% vs 82%), major cytogenetic response (MCyR) (53% vs 33%), and complete cytogenetic response (44% vs 18%).
- At 18 mos, MCyR was maintained in 90% of pts on the dasatinib arm and in 74% of pts on the high-dose imatinib arm.
- Major molecular response rates were more frequent with dasatinib than with high-dose imatinib (29% vs 12%).
- Estimated PFS also favored dasatinib.
Today in Chemotherapy/Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Palliative Oncology: Thalidomide
American Journal of Hospice and Palliative Medicine, 10/21/09
Current status of maintenance therapy for advanced ovarian cancer
International Journal of Women's Health, 11/03/09
Aspirin use associated with lower colorectal cancer mortality
American Pharmacists Association, 10/14/09
Today in Dosing...keeping you current
Receive free subspecialty "5-minute updates" via email
Drug dosage protocol for calcium oxalate stone
Urological Research - Urolithiasis, 10/23/09
Risperidone dose for schizophrenia
Cochrane Reviews, 10/21/09
Pediatric antifungal agents
Current Opinion in Infectious Diseases, 10/28/09
Today in Drug Resistance...keeping you current
Receive free subspecialty "5-minute updates" via email
Monotherapy versus combination therapy for the treatment of chronic hepatitis B
Expert Opinion on Investigational Drugs, 10/26/09
Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends
Clinical Therapeutics, 10/15/09
VanA-Type Vancomycin-Resistant Staphylococcus aureus
Antimicrobial Agents and Chemotherapy, 11/05/09
Sponsor
Article Search
Sponsor